OmniAb, Inc.
OABIW
NASDAQ Capital Market0.10
USD
+0.00
- -
OmniAb, Inc.
OABIW
(NASDAQ Capital Market)
Recent
price
0.10
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- OmniAb, Inc. (OABIW) is a biotechnology company that licenses proprietary discovery research technologies to pharmaceutical and biotech companies, as well as academic institutions, to enable the development of next-generation therapeutics through diverse antibody repertoires and advanced screening platforms. The company offers a comprehensive suite of transgenic animal platforms powered by Biological Intelligence, including OmniRat, OmniChicken, OmniMouse, OmniFlic, OmniClic, OmniTaur, and OmnidAb for generating fully human or humanized antibodies, single-domain antibodies, and cow-inspired structures suitable for challenging targets; these support modalities such as bi- and multi-specific biologics, antibody-drug conjugates, CAR-T therapies, and targeted radiotherapeutics. Complementary technologies encompass OmniDeep, a suite of in silico AI and machine learning tools for discovery and optimization, alongside high-throughput single B-cell screening, computational antigen design, and specialized capabilities in ion channels and transporters. Founded in 2012 and headquartered in Emeryville, California, OmniAb operates globally, serving over 100 active partners across biopharmaceutical firms and research institutions with 399 active programs as of September 30, 2025, including 32 in clinical development or commercialization. In recent developments, the company launched the xPloration high-throughput single B-cell screening platform in 2025, featuring instruments, proprietary consumables, and software subscriptions to enhance partner efficiencies; it completed a $30 million private placement to bolster its balance sheet; and entered multiple new license agreements in 2025, including with Veraxa Biotech, Duke-NUS, University of Strathclyde, A*Star, University of Leeds, and Dana-Farber Cancer Institute. OmniAb anticipates the December 2025 launch of OmniUltra, a transgenic chicken platform producing antibodies with ultralong CDRH3s for accessing difficult binding pockets, further expanding its offerings amid 36 net program additions year-to-date through Q3 2025.